Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospitals Look To Imaging Industry For Help In Treating The Morbidly Obese

This article was originally published in The Gray Sheet

Executive Summary

As the U.S. obesity rate continues to climb, imaging equipment vendors are answering hospitals' demand for machines that can accommodate larger patients

You may also be interested in...



GE Healthcare launches Optima MR450w

New wide-bore magnetic resonance imaging system addresses market for large systems with high-quality imaging, the company says. Optima MR450w allows scans with a 50 cm field of view, while the 70 cm-wide bore allows "enhanced patient comfort" for obese or claustrophobic patients, GE says Aug. 24. The system, which was 510(k)-cleared July 28, is "clinically optimized to specific anatomies, including industry-leading breast imaging capabilities, [and] can accommodate more patients with fewer scans and less coaxing for high patient throughput," the company claims. GE adds that the Optima MR450w has overcome limitations that previously sacrificed image quality for size of scan, and that it is "one of GE Healthcare's largest launches for this year." Radiologists previously have emphasized a need for imaging equipment to accommodate heavy patients (1"The Gray Sheet" Aug. 3, 2009)

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel